Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2024

Open Access 01-12-2024 | Arterial Diseases | Research

Risk analysis of the association between different hemoglobin glycation index and poor prognosis in critical patients with coronary heart disease-A study based on the MIMIC-IV database

Authors: Xing Wei, Xinghua Chen, Zhipeng Zhang, Jing Wei, Ben Hu, Nv Long, Jun Feng, Chunmiao Luo

Published in: Cardiovascular Diabetology | Issue 1/2024

Login to get access

Abstract

Background

The hemoglobin glycation index (HGI) is the difference between the observed and predicted values of glycosylated hemoglobin (HbA1c), which is closely associated with a variety of poor prognoses. However, there are still no studies on the correlation between HGI and poor prognosis in patients with critical coronary artery disease. The purpose of this study was to analyze the correlation between HGI and all-cause mortality in patients with critical coronary artery disease using the MIMIC-IV database.

Methods

The HGI was calculated by constructing a linear regression equation between HbA1c and fasting plasma glucose (FPG). A Kaplan‒Meier survival analysis model was constructed based on the HGI quartiles to clarify the differences in all-cause mortality rates between groups, and the log-rank test was used to assess the differences between groups. The hazard ratio (HR) of HGI as a risk factor for outcome events was assessed using the Cox proportional risk model and restricted cubic spline (RCS), with the Q2 group serving as the reference group.

Results

A total of 5260 patients were included in this study. The 30-day mortality rate of the patients was 4.94% and the mortality rate within 365 days was 13.12%. A low HGI was significantly associated with 30-day mortality (HR, 1.96; 95% CI, (1.38, 2.78); P < 0.001) and 365-day mortality (HR, 1.48; 95% CI, (1.19, 1.85); P < 0.001) in patients with critical coronary artery disease in the completely adjusted Cox proportional risk model. In addition, high levels of HGI were associated with 365-day mortality (HR, 1.31; 95% CI, (1.02, 1.69); P < 0.05). RCS analysis revealed a U-shaped relationship between HGI and outcome events. According to the stratified analysis, the interaction test revealed that the correlation between HGI and outcome events remained stable.

Conclusion

There was a significant correlation between HGI and all-cause mortality in patients with critical coronary artery disease, particularly in those with low HGI. HGI can be used as a potential indicator for assessing the short- and long-term risk of mortality in such patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Hasbani NR, Ligthart S, Brown MR, Heath AS, Bebo A, Ashley KE, Boerwinkle E, Morrison AC, Folsom AR, Aguilar D, de Vries PS. American Heart Association’s life’s simple 7: lifestyle recommendations, polygenic risk, and lifetime risk of Coronary Heart Disease. Circulation. 2022;145(11):808–18.CrossRefPubMedPubMedCentral Hasbani NR, Ligthart S, Brown MR, Heath AS, Bebo A, Ashley KE, Boerwinkle E, Morrison AC, Folsom AR, Aguilar D, de Vries PS. American Heart Association’s life’s simple 7: lifestyle recommendations, polygenic risk, and lifetime risk of Coronary Heart Disease. Circulation. 2022;145(11):808–18.CrossRefPubMedPubMedCentral
2.
go back to reference Luo W, Cao L, Wang C. Low body temperature and mortality in critically ill patients with coronary heart disease: a retrospective analysis from MIMIC-IV database. Eur J Med Res. 2023;28(1):614.CrossRefPubMedPubMedCentral Luo W, Cao L, Wang C. Low body temperature and mortality in critically ill patients with coronary heart disease: a retrospective analysis from MIMIC-IV database. Eur J Med Res. 2023;28(1):614.CrossRefPubMedPubMedCentral
3.
go back to reference Mayr VD, Dünser MW, Greil V, Jochberger S, Luckner G, Ulmer H, Friesenecker BE, Takala J, Hasibeder WR. Causes of death and determinants of outcome in critically ill patients. Crit Care (London England). 2006;10(6):R154.CrossRef Mayr VD, Dünser MW, Greil V, Jochberger S, Luckner G, Ulmer H, Friesenecker BE, Takala J, Hasibeder WR. Causes of death and determinants of outcome in critically ill patients. Crit Care (London England). 2006;10(6):R154.CrossRef
4.
go back to reference Wang Y, O’Neil A, Jiao Y, Wang L, Huang J, Lan Y, Zhu Y, Yu C. Sex differences in the association between diabetes and risk of cardiovascular disease, cancer, and all-cause and cause-specific mortality: a systematic review and meta-analysis of 5,162,654 participants. BMC Med. 2019;17(1):136.CrossRefPubMedPubMedCentral Wang Y, O’Neil A, Jiao Y, Wang L, Huang J, Lan Y, Zhu Y, Yu C. Sex differences in the association between diabetes and risk of cardiovascular disease, cancer, and all-cause and cause-specific mortality: a systematic review and meta-analysis of 5,162,654 participants. BMC Med. 2019;17(1):136.CrossRefPubMedPubMedCentral
5.
go back to reference Peters SA, Huxley RR, Woodward M. Diabetes as risk factor for incident coronary heart disease in women compared with men: a systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events. Diabetologia. 2014;57(8):1542–51.CrossRefPubMed Peters SA, Huxley RR, Woodward M. Diabetes as risk factor for incident coronary heart disease in women compared with men: a systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events. Diabetologia. 2014;57(8):1542–51.CrossRefPubMed
6.
go back to reference Natali A, Vichi S, Landi P, Severi S, L’Abbate A, Ferrannini E. Coronary atherosclerosis in type II diabetes: angiographic findings and clinical outcome. Diabetologia. 2000;43(5):632–41.CrossRefPubMed Natali A, Vichi S, Landi P, Severi S, L’Abbate A, Ferrannini E. Coronary atherosclerosis in type II diabetes: angiographic findings and clinical outcome. Diabetologia. 2000;43(5):632–41.CrossRefPubMed
7.
go back to reference Malik S, Wong ND, Franklin SS, Kamath TV, L’Italien GJ, Pio JR, Williams GR. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004;110(10):1245–50.CrossRefPubMed Malik S, Wong ND, Franklin SS, Kamath TV, L’Italien GJ, Pio JR, Williams GR. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004;110(10):1245–50.CrossRefPubMed
8.
go back to reference Verma S, Mazer CD, Yan AT, Mason T, Garg V, Teoh H, Zuo F, Quan A, Farkouh ME, Fitchett DH, Goodman SG, Goldenberg RM, Al-Omran M, Gilbert RE, Bhatt DL, Leiter LA, Jüni P, Zinman B, Connelly KA. Effect of Empagliflozin on Left Ventricular Mass in patients with type 2 diabetes Mellitus and Coronary Artery Disease: the EMPA-HEART CardioLink-6 Randomized Clinical Trial. Circulation. 2019;140(21):1693–702.CrossRefPubMed Verma S, Mazer CD, Yan AT, Mason T, Garg V, Teoh H, Zuo F, Quan A, Farkouh ME, Fitchett DH, Goodman SG, Goldenberg RM, Al-Omran M, Gilbert RE, Bhatt DL, Leiter LA, Jüni P, Zinman B, Connelly KA. Effect of Empagliflozin on Left Ventricular Mass in patients with type 2 diabetes Mellitus and Coronary Artery Disease: the EMPA-HEART CardioLink-6 Randomized Clinical Trial. Circulation. 2019;140(21):1693–702.CrossRefPubMed
9.
go back to reference Sarak B, Verma S, David Mazer C, Teoh H, Quan A, Gilbert RE, Goodman SG, Bami K, Coelho-Filho OR, Ahooja V, Deva DP, Garg V, Gandhi S, Connelly KA, Yan AT. Impact of empagliflozin on right ventricular parameters and function among patients with type 2 diabetes. Cardiovasc Diabetol. 2021;20(1):200.CrossRefPubMedPubMedCentral Sarak B, Verma S, David Mazer C, Teoh H, Quan A, Gilbert RE, Goodman SG, Bami K, Coelho-Filho OR, Ahooja V, Deva DP, Garg V, Gandhi S, Connelly KA, Yan AT. Impact of empagliflozin on right ventricular parameters and function among patients with type 2 diabetes. Cardiovasc Diabetol. 2021;20(1):200.CrossRefPubMedPubMedCentral
10.
go back to reference Yang G, Au Yeung SL, Schooling CM. Sex differences in the association of fasting glucose with HbA1c, and their consequences for mortality: a mendelian randomization study. EBioMedicine. 2022;84:104259.CrossRefPubMedPubMedCentral Yang G, Au Yeung SL, Schooling CM. Sex differences in the association of fasting glucose with HbA1c, and their consequences for mortality: a mendelian randomization study. EBioMedicine. 2022;84:104259.CrossRefPubMedPubMedCentral
11.
go back to reference van Steen SC, Woodward M, Chalmers J, Li Q, Marre M, Cooper ME, Hamet P, Mancia G, Colagiuri S, Williams B, Grobbee DE, DeVries JH. Haemoglobin glycation index and risk for diabetes-related complications in the action in diabetes and vascular disease: Preterax and Diamicron Modified Release Controlled evaluation (ADVANCE) trial. Diabetologia. 2018;61(4):780–9.CrossRefPubMedPubMedCentral van Steen SC, Woodward M, Chalmers J, Li Q, Marre M, Cooper ME, Hamet P, Mancia G, Colagiuri S, Williams B, Grobbee DE, DeVries JH. Haemoglobin glycation index and risk for diabetes-related complications in the action in diabetes and vascular disease: Preterax and Diamicron Modified Release Controlled evaluation (ADVANCE) trial. Diabetologia. 2018;61(4):780–9.CrossRefPubMedPubMedCentral
12.
go back to reference Hempe JM, Gomez R, McCarter RJ Jr., Chalew SA. High and low hemoglobin glycation phenotypes in type 1 diabetes: a challenge for interpretation of glycemic control. J Diabetes Complicat. 2002;16(5):313–20.CrossRef Hempe JM, Gomez R, McCarter RJ Jr., Chalew SA. High and low hemoglobin glycation phenotypes in type 1 diabetes: a challenge for interpretation of glycemic control. J Diabetes Complicat. 2002;16(5):313–20.CrossRef
13.
go back to reference Malka R, Nathan DM, Higgins JM. Mechanistic modeling of hemoglobin glycation and red blood cell kinetics enables personalized diabetes monitoring. Sci Transl Med. 2016;8(359):359ra130.CrossRefPubMedPubMedCentral Malka R, Nathan DM, Higgins JM. Mechanistic modeling of hemoglobin glycation and red blood cell kinetics enables personalized diabetes monitoring. Sci Transl Med. 2016;8(359):359ra130.CrossRefPubMedPubMedCentral
14.
go back to reference Khera PK, Joiner CH, Carruthers A, Lindsell CJ, Smith EP, Franco RS, Holmes YR, Cohen RM. Evidence for interindividual heterogeneity in the glucose gradient across the human red blood cell membrane and its relationship to hemoglobin glycation. Diabetes. 2008;57(9):2445–52.CrossRefPubMedPubMedCentral Khera PK, Joiner CH, Carruthers A, Lindsell CJ, Smith EP, Franco RS, Holmes YR, Cohen RM. Evidence for interindividual heterogeneity in the glucose gradient across the human red blood cell membrane and its relationship to hemoglobin glycation. Diabetes. 2008;57(9):2445–52.CrossRefPubMedPubMedCentral
15.
go back to reference Brown SM, Smith DM, Alt N, Thorpe SR, Baynes JW. Tissue-specific variation in glycation of proteins in diabetes: evidence for a functional role of amadoriase enzymes. Volume 1043. Annals of the New York Academy of Sciences; 2005. pp. 817–23. Brown SM, Smith DM, Alt N, Thorpe SR, Baynes JW. Tissue-specific variation in glycation of proteins in diabetes: evidence for a functional role of amadoriase enzymes. Volume 1043. Annals of the New York Academy of Sciences; 2005. pp. 817–23.
16.
go back to reference Hempe JM, Liu S, Myers L, McCarter RJ, Buse JB, Fonseca V. The hemoglobin glycation index identifies subpopulations with harms or benefits from intensive treatment in the ACCORD trial. Diabetes Care. 2015;38(6):1067–74.CrossRefPubMedPubMedCentral Hempe JM, Liu S, Myers L, McCarter RJ, Buse JB, Fonseca V. The hemoglobin glycation index identifies subpopulations with harms or benefits from intensive treatment in the ACCORD trial. Diabetes Care. 2015;38(6):1067–74.CrossRefPubMedPubMedCentral
17.
go back to reference Klein KR, Franek E, Marso S, Pieber TR, Pratley RE, Gowda A, Kvist K, Buse JB. Hemoglobin glycation index, calculated from a single fasting glucose value, as a prediction tool for severe hypoglycemia and major adverse cardiovascular events in DEVOTE. Volume 9. BMJ open diabetes research & care; 2021. 2. Klein KR, Franek E, Marso S, Pieber TR, Pratley RE, Gowda A, Kvist K, Buse JB. Hemoglobin glycation index, calculated from a single fasting glucose value, as a prediction tool for severe hypoglycemia and major adverse cardiovascular events in DEVOTE. Volume 9. BMJ open diabetes research & care; 2021. 2.
18.
go back to reference Wang Y, Liu H, Hu X, Wang A, Wang A, Kang S, Zhang L, Gu W, Dou J, Mu Y, Chen K, Wang W, Lyu Z. Association between hemoglobin glycation index and 5-year major adverse cardiovascular events: the REACTION cohort study. Chin Med J. 2023;136(20):2468–75.CrossRefPubMedPubMedCentral Wang Y, Liu H, Hu X, Wang A, Wang A, Kang S, Zhang L, Gu W, Dou J, Mu Y, Chen K, Wang W, Lyu Z. Association between hemoglobin glycation index and 5-year major adverse cardiovascular events: the REACTION cohort study. Chin Med J. 2023;136(20):2468–75.CrossRefPubMedPubMedCentral
19.
go back to reference Pan Y, Jing J, Wang Y, Liu L, Wang Y, He Y. Association of hemoglobin glycation index with outcomes of acute ischemic stroke in type 2 diabetic patients. Neurol Res. 2018;40(7):573–80.CrossRefPubMed Pan Y, Jing J, Wang Y, Liu L, Wang Y, He Y. Association of hemoglobin glycation index with outcomes of acute ischemic stroke in type 2 diabetic patients. Neurol Res. 2018;40(7):573–80.CrossRefPubMed
20.
go back to reference Adeva-Andany MM, Martínez-Rodríguez J, González-Lucán M, Fernández-Fernández C, Castro-Quintela E. Insulin resistance is a cardiovascular risk factor in humans. Diabetes Metabolic Syndrome. 2019;13(2):1449–55.CrossRefPubMed Adeva-Andany MM, Martínez-Rodríguez J, González-Lucán M, Fernández-Fernández C, Castro-Quintela E. Insulin resistance is a cardiovascular risk factor in humans. Diabetes Metabolic Syndrome. 2019;13(2):1449–55.CrossRefPubMed
21.
go back to reference Lyu L, Yu J, Liu Y, He S, Zhao Y, Qi M, Ping F, Xu L, Li W, Zhang H, Li Y. High Hemoglobin Glycation Index is Associated with Telomere Attrition Independent of HbA1c, mediated by TNFα. J Clin Endocrinol Metab. 2022;107(2):462–73.CrossRefPubMed Lyu L, Yu J, Liu Y, He S, Zhao Y, Qi M, Ping F, Xu L, Li W, Zhang H, Li Y. High Hemoglobin Glycation Index is Associated with Telomere Attrition Independent of HbA1c, mediated by TNFα. J Clin Endocrinol Metab. 2022;107(2):462–73.CrossRefPubMed
22.
go back to reference Johnson AEW, Bulgarelli L, Shen L, Gayles A, Shammout A, Horng S, Pollard TJ, Hao S, Moody B, Gow B, Lehman LH, Celi LA, Mark RG. MIMIC-IV, a freely accessible electronic health record dataset. Sci data. 2023;10(1):1.CrossRefPubMedPubMedCentral Johnson AEW, Bulgarelli L, Shen L, Gayles A, Shammout A, Horng S, Pollard TJ, Hao S, Moody B, Gow B, Lehman LH, Celi LA, Mark RG. MIMIC-IV, a freely accessible electronic health record dataset. Sci data. 2023;10(1):1.CrossRefPubMedPubMedCentral
23.
go back to reference Cheng Y, Chen Y, Mao M, Wang R, Zhu J, He Q. Association of inflammatory indicators with intensive care unit mortality in critically ill patients with coronary heart disease. Front Immunol. 2023;14:1295377.CrossRefPubMedPubMedCentral Cheng Y, Chen Y, Mao M, Wang R, Zhu J, He Q. Association of inflammatory indicators with intensive care unit mortality in critically ill patients with coronary heart disease. Front Immunol. 2023;14:1295377.CrossRefPubMedPubMedCentral
24.
go back to reference Chen Z, Li D, Lin M, Jiang H, Xu T, Shan Y, Fu G, Wang M, Zhang W. Association of Hemoglobin Glycation Index with contrast-Induced Acute kidney Injury in patients undergoing coronary angiography: a retrospective study. Front Physiol. 2022;13:870694.CrossRefPubMedPubMedCentral Chen Z, Li D, Lin M, Jiang H, Xu T, Shan Y, Fu G, Wang M, Zhang W. Association of Hemoglobin Glycation Index with contrast-Induced Acute kidney Injury in patients undergoing coronary angiography: a retrospective study. Front Physiol. 2022;13:870694.CrossRefPubMedPubMedCentral
25.
go back to reference Nakasone Y, Miyakoshi T, Sakuma T, Toda S, Yamada Y, Oguchi T, Hirabayashi K, Koike H, Yamashita K, Aizawa T. Hemoglobin glycation index, a novel risk factor for incident chronic kidney disease in apparently healthy Population. The Journal of clinical endocrinology and metabolism 2023. Nakasone Y, Miyakoshi T, Sakuma T, Toda S, Yamada Y, Oguchi T, Hirabayashi K, Koike H, Yamashita K, Aizawa T. Hemoglobin glycation index, a novel risk factor for incident chronic kidney disease in apparently healthy Population. The Journal of clinical endocrinology and metabolism 2023.
26.
go back to reference Wang M, Li S, Zhang X, Li X, Cui J. Association between hemoglobin glycation index and non-alcoholic fatty liver disease in the patients with type 2 diabetes mellitus. J Diabetes Invest. 2023;14(11):1303–11.CrossRef Wang M, Li S, Zhang X, Li X, Cui J. Association between hemoglobin glycation index and non-alcoholic fatty liver disease in the patients with type 2 diabetes mellitus. J Diabetes Invest. 2023;14(11):1303–11.CrossRef
27.
go back to reference Bookchin RM, Gallop PM. Structure of hemoglobin AIc: nature of the N-terminal beta chain blocking group. Biochem Biophys Res Commun. 1968;32(1):86–93.CrossRefPubMed Bookchin RM, Gallop PM. Structure of hemoglobin AIc: nature of the N-terminal beta chain blocking group. Biochem Biophys Res Commun. 1968;32(1):86–93.CrossRefPubMed
28.
go back to reference McCarter RJ, Hempe JM, Gomez R, Chalew SA. Biological variation in HbA1c predicts risk of retinopathy and nephropathy in type 1 diabetes. Diabetes Care. 2004;27(6):1259–64.CrossRefPubMed McCarter RJ, Hempe JM, Gomez R, Chalew SA. Biological variation in HbA1c predicts risk of retinopathy and nephropathy in type 1 diabetes. Diabetes Care. 2004;27(6):1259–64.CrossRefPubMed
29.
go back to reference Carette C, Czernichow S. Harms and benefits of the haemoglobin glycation index (HGI). Eur J Prev Cardiol. 2017;24(13):1402–4.CrossRefPubMed Carette C, Czernichow S. Harms and benefits of the haemoglobin glycation index (HGI). Eur J Prev Cardiol. 2017;24(13):1402–4.CrossRefPubMed
30.
go back to reference Chen J, Yin D, Dou K. Intensified glycemic control by HbA1c for patients with coronary heart disease and type 2 diabetes: a review of findings and conclusions. Cardiovasc Diabetol. 2023;22(1):146.CrossRefPubMedPubMedCentral Chen J, Yin D, Dou K. Intensified glycemic control by HbA1c for patients with coronary heart disease and type 2 diabetes: a review of findings and conclusions. Cardiovasc Diabetol. 2023;22(1):146.CrossRefPubMedPubMedCentral
31.
go back to reference You H, Hou X, Zhang H, Li X, Feng X, Qian X, Shi N, Guo R, Wang X, Sun H, Feng W, Li G, Zheng Z, Chen Y. Effect of glycemic control and glucose fluctuation on in-hospital adverse outcomes after on-pump coronary artery bypass grafting in patients with diabetes: a retrospective study. Diabetol Metab Syndr. 2023;15(1):20.CrossRefPubMedPubMedCentral You H, Hou X, Zhang H, Li X, Feng X, Qian X, Shi N, Guo R, Wang X, Sun H, Feng W, Li G, Zheng Z, Chen Y. Effect of glycemic control and glucose fluctuation on in-hospital adverse outcomes after on-pump coronary artery bypass grafting in patients with diabetes: a retrospective study. Diabetol Metab Syndr. 2023;15(1):20.CrossRefPubMedPubMedCentral
32.
go back to reference Riddle MC, Gerstein HC et al. Comment on Hempe The hemoglobin glycation index identifies subpopulations with harms or benefits from intensive treatment in the ACCORD trial. Diabetes Care. 2015;38:1067–1074. Diabetes care 2015, 38 (10), e170-1. Riddle MC, Gerstein HC et al. Comment on Hempe The hemoglobin glycation index identifies subpopulations with harms or benefits from intensive treatment in the ACCORD trial. Diabetes Care. 2015;38:1067–1074. Diabetes care 2015, 38 (10), e170-1.
33.
go back to reference Ahn CH, Min SH, Lee DH, Oh TJ, Kim KM, Moon JH, Choi SH, Park KS, Jang HC, Ha J, Sherman AS, Lim S. Hemoglobin glycation index is Associated with Cardiovascular diseases in people with impaired glucose metabolism. J Clin Endocrinol Metab. 2017;102(8):2905–13.CrossRefPubMedPubMedCentral Ahn CH, Min SH, Lee DH, Oh TJ, Kim KM, Moon JH, Choi SH, Park KS, Jang HC, Ha J, Sherman AS, Lim S. Hemoglobin glycation index is Associated with Cardiovascular diseases in people with impaired glucose metabolism. J Clin Endocrinol Metab. 2017;102(8):2905–13.CrossRefPubMedPubMedCentral
34.
go back to reference Meigs JB, Nathan DM, D’Agostino RB, Wilson S. Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham offspring study. Diabetes Care. 2002;25(10):1845–50.CrossRefPubMed Meigs JB, Nathan DM, D’Agostino RB, Wilson S. Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham offspring study. Diabetes Care. 2002;25(10):1845–50.CrossRefPubMed
35.
go back to reference Gao S, Huang S, Lin X, Xu L, Yu M. Prognostic implications of stress hyperglycemia ratio in patients with myocardial infarction with nonobstructive coronary arteries. Ann Med. 2023;55(1):990–9.CrossRefPubMedPubMedCentral Gao S, Huang S, Lin X, Xu L, Yu M. Prognostic implications of stress hyperglycemia ratio in patients with myocardial infarction with nonobstructive coronary arteries. Ann Med. 2023;55(1):990–9.CrossRefPubMedPubMedCentral
36.
go back to reference Yang J, Zheng Y, Li C, Gao J, Meng X, Zhang K, Wang W, Shao C, Tang YD. The impact of the stress hyperglycemia ratio on short-term and long-term poor prognosis in patients with Acute Coronary Syndrome: insight from a large cohort study in Asia. Diabetes Care. 2022;45(4):947–56.CrossRefPubMed Yang J, Zheng Y, Li C, Gao J, Meng X, Zhang K, Wang W, Shao C, Tang YD. The impact of the stress hyperglycemia ratio on short-term and long-term poor prognosis in patients with Acute Coronary Syndrome: insight from a large cohort study in Asia. Diabetes Care. 2022;45(4):947–56.CrossRefPubMed
37.
go back to reference Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet (London England). 2000;355(9206):773–8.CrossRefPubMed Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet (London England). 2000;355(9206):773–8.CrossRefPubMed
Metadata
Title
Risk analysis of the association between different hemoglobin glycation index and poor prognosis in critical patients with coronary heart disease-A study based on the MIMIC-IV database
Authors
Xing Wei
Xinghua Chen
Zhipeng Zhang
Jing Wei
Ben Hu
Nv Long
Jun Feng
Chunmiao Luo
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2024
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-024-02206-1

Other articles of this Issue 1/2024

Cardiovascular Diabetology 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine